Charlotta Liljebris
Chief Tech/Sci/R&D Officer chez XSPRAY PHARMA AB
Profil
Charlotta Liljebris is currently the Deputy Director at Liljebris Consulting Ab and the Vice President-Research & Development at Xspray Pharma AB.
Previously, she worked as an Independent Director at Sprint Bioscience AB, Director at Recipharm OT Chemistry AB, Director at Connect Uppsala, Principal at Biovitrum AB, and Vice President-Development at Aprea Therapeutics AB.
Dr. Liljebris holds a graduate and doctorate degree from the University of Uppsala.
Postes actifs de Charlotta Liljebris
| Sociétés | Poste | Début |
|---|---|---|
| XSPRAY PHARMA AB | Chief Tech/Sci/R&D Officer | 01/01/2018 |
| Liljebris Consulting Ab | Corporate Officer/Principal | - |
Anciens postes connus de Charlotta Liljebris
| Sociétés | Poste | Fin |
|---|---|---|
| Connect Uppsala | Director/Board Member | - |
Recipharm OT Chemistry AB
 Recipharm OT Chemistry AB Pharmaceuticals: MajorHealth Technology Part of Recipharm AB, Recipharm OT Chemistry AB develops and manufactures drug dosage forms and inhalation products & devices. The private company is based in Uppsala, Sweden. | Director/Board Member | - |
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Corporate Officer/Principal | - |
| SPRINT BIOSCIENCE AB | Director/Board Member | - |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Corporate Officer/Principal | - |
Formation de Charlotta Liljebris
| University of Uppsala | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| XSPRAY PHARMA AB | Health Technology |
| SPRINT BIOSCIENCE AB | Health Technology |
| Entreprise privées | 5 |
|---|---|
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Recipharm OT Chemistry AB
Recipharm OT Chemistry AB Pharmaceuticals: MajorHealth Technology Part of Recipharm AB, Recipharm OT Chemistry AB develops and manufactures drug dosage forms and inhalation products & devices. The private company is based in Uppsala, Sweden. | Health Technology |
| Liljebris Consulting Ab | |
| Connect Uppsala |
